Through the IMPRIME Cancer Immunotherapy Clinical Trials, Biothera Pharmaceuticals is evaluating the safety and efficacy of combining Imprime PGG and immune checkpoint inhibitor therapies (anti-PD-1 and anti-PD-L1 antibodies) in multiple cancer indications.
IMPRIME 1 is a Phase 2 clinical study assessing the effectiveness of Imprime PGG in combination with Merck’s Keytruda® (pembrolizumab) in patients with metastatic triple negative breast cancer or advanced melanoma whose disease has progressed following prior treatment with checkpoint inhibitor therapy or chemotherapy.
Biothera is collaborating with Genentech, Inc., a member of the Roche Group, which is conducting a Phase 2 trial to assess the safety and efficacy of Biothera’s Imprime PGG in combination with Genentech’s Tecentriq® (atezolizumab) and Avastin® (bevacizumab) to treat patients with metastatic colorectal cancer.
In addition, Biothera Pharmaceuticals is collaborating with the Big Ten Cancer Research Consortium under a grant from Merck, to evaluate Imprime PGG and Keytruda in a Phase 1b/2 non-small cell lung cancer study.
Imprime PGG has been administered to more than 400 cancer patients in multiple combination regimens (checkpoint inhibitors, monoclonal antibodies, chemotherapies). Imprime PGG has not been shown to exacerbate adverse effects of combination therapies and additive side effects were manageable and reversible.